Prestige Consumer Healthcare (PBH) Projected to Post Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is expected to be releasing its Q2 2026 results before the market opens on Thursday, November 6th. Analysts expect Prestige Consumer Healthcare to post earnings of $1.01 per share and revenue of $257.1380 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS.Interested persons are encouraged to explore the company’s upcoming Q2 2026 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The business had revenue of $249.53 million for the quarter, compared to analysts’ expectations of $260.71 million. During the same quarter in the prior year, the firm posted $0.90 EPS. The business’s quarterly revenue was down 6.6% compared to the same quarter last year. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $60.56 on Thursday. Prestige Consumer Healthcare has a 1-year low of $60.15 and a 1-year high of $90.04. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of 14.22, a P/E/G ratio of 1.97 and a beta of 0.44. The stock’s fifty day simple moving average is $63.85 and its 200-day simple moving average is $74.16.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its position in Prestige Consumer Healthcare by 19.1% during the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after purchasing an additional 115,459 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Prestige Consumer Healthcare by 12.9% during the second quarter. The Manufacturers Life Insurance Company now owns 553,407 shares of the company’s stock valued at $44,190,000 after purchasing an additional 63,168 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Prestige Consumer Healthcare by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after purchasing an additional 120,965 shares during the last quarter. Public Sector Pension Investment Board lifted its position in shares of Prestige Consumer Healthcare by 6.2% in the second quarter. Public Sector Pension Investment Board now owns 189,134 shares of the company’s stock worth $15,102,000 after buying an additional 11,115 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Prestige Consumer Healthcare by 25.3% in the second quarter. Jane Street Group LLC now owns 131,337 shares of the company’s stock worth $10,487,000 after buying an additional 26,535 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PBH. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Zacks Research downgraded Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Thursday, September 4th. Jefferies Financial Group lowered their price target on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a report on Monday. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Oppenheimer lowered their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a report on Tuesday, October 21st. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Hold” and an average target price of $87.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.